Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Clinical pharmacology of topiramate: a review Garnett WREpilepsia 2000[]; 41 (S1): 61-5Clinical success with an antiepileptic drug (AED) depends primarily on its efficacy and tolerability. Clinicians also need to have a basic understanding of an AED's pharmacokinetic characteristics, particularly those affecting the potential for drug interactions such as hepatic enzyme inhibition or induction and protein-binding displacement. Successful treatment may be complicated by pharmacokinetic characteristics such as a short half-life, nonlinear kinetics, and active metabolites. Pharmacokinetic characteristics that make a drug easy to use may affect patient adherence. In general, newer AEDs such as topiramate (TPM) are simpler to use than traditional AEDs because they have more favorable pharmacokinetic characteristics and fewer drug interactions.|Adolescent[MESH]|Age Factors[MESH]|Aged[MESH]|Anticonvulsants/*pharmacokinetics/pharmacology/therapeutic use[MESH]|Biological Availability[MESH]|Child[MESH]|Child, Preschool[MESH]|Drug Interactions[MESH]|Epilepsy/*drug therapy/metabolism[MESH]|Food-Drug Interactions[MESH]|Fructose/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use[MESH]|Half-Life[MESH]|Humans[MESH]|Intestinal Absorption[MESH]|Patient Compliance[MESH]|Pharmacokinetics[MESH]|Tissue Distribution[MESH]|Topiramate[MESH] |
